Also from this source

You just read:

Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease

News provided by

Accera, Inc.

Jul 14, 2015, 08:00 ET